CYVADIC                                              sarcoma(131)
 _________________________________________________________________
  cytoxan......... 500 [400] mg/sqm IV day 1.
  vincristine..... 1 [1] mg/sqm (maximum single dose 1.5 mg) IV on 
                   days 1 and 5.
  adriamycin...... 50 [40] mg/sqm IV day 1.
  dacarbazine..... 250 [200] mg/sqm/day from day 1 to day 5.
  FREQUENCY....... Repeat cycle every 21 days.


  reference...
    Yap BS.  Baker LH.  Sinkovics JG.  Rivkin SE.  Bottomley R. 
    Thigpen T.  Burgess MA.  Benjamin RS.  Bodey GP. 
    Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) 
    combination chemotherapy for the treatment of advanced 
    sarcomas. Cancer Treatment Reports.  64(1):93-8, 1980 Jan. 
  abstract...
    One hundred and forty adult patients with advanced sarcomas 
    (125 soft tissue and 15 bone) were treated with a combination 
    chemotherapy regimen consisting of cyclophosphamide, 
    vincristine, Adriamycin, and DTIC (CYVADIC). There were 21 
    (15%) complete and 45 (32%) partial responders, with an 
    overall response rate of 47%. The response rate was 50% (17% 
    complete) for patients with soft tissue sarcomas compared with 
    20% (none complete) for patients with bone sarcomas. The 
    median duration of response was 9.5 months (range, 1-40+ 
    months) for complete responders and 7 months (range, 1-31 
    months) for partial responders. The median time to achieve 
    response was 9 weeks and the median number of courses of 
    therapy to response was three. The median survival time was 16 
    months for responders compared with 7 months for nonresponders 
    (P = 0.001). The most responsive tumor types were 
    neurofibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, 
    fibrosarcoma, and angiosarcoma. Pulmonary and soft tissue 
    metastases were more responsive than bone and liver 
    metastases. CYVADIC toxicity was predominantly limited to 
    myelosuppression, vomiting, fever of unknown origin, and 
    neuropathy. CYVADIC is an effective combination chemotherapy 
    regimen in the treatment of advanced sarcomas.